Patients with dermatomyositis with at least two clinical risk factors (such as older age, male gender, dysphagia, cutaneous necrosis or ulcerations, vasculitis, rapid onset of IIM, refractory course of IIM, high concentrations of muscle enzymes and inflammatory markers) and no protective factors (ILD, inflammatory arthropathy, Raynaud phenomenon), as well as patients with anti-TIF1-γ and anti-NXP-2 antibodies were considered high-risk groups. This evidence concerns the gene MORC3 and dermatomyositis.